Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Human interleukin-2. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Human interleukin-2. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Human interleukin-2. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Human interleukin-2. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Human interleukin-2. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Human interleukin-2 is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Human interleukin-2 is combined with Etrasimod. |